Welcome to our dedicated page for Fifty 1 Labs news (Ticker: FITY), a resource for investors and traders seeking the latest updates and insights on Fifty 1 Labs stock.
Fifty 1 Labs, Inc. develops biotechnology and life sciences initiatives centered on peptide products, peptide discovery, AI-enabled research, and clinical development for musculoskeletal health, recovery, and performance. News about FITY commonly covers the company’s transition into peptide biotechnology, its use of artificial intelligence in discovery and research, and program areas involving muscle, tendon, ligament, bone, pain management, injury recovery, and personalized wellness.
Company updates also address capital-structure actions, including the retirement of Series B Preferred Stock to reduce potential common-share dilution, as well as governance, audit, and corporate-status developments. Recent corporate communications have clarified the status of former subsidiary relationships and prior collaboration references while keeping the company’s current focus on peptide therapeutics and wellness-oriented life sciences.
Fifty1 Labs (OTC:FITY) and BioSpark AI Technologies have achieved a significant milestone in AI-driven drug repurposing by transforming 10,000+ unstructured case reports into a database of 2,000+ real-world treatment pathways. The collaboration, which includes a planned acquisition of BioSpark AI, combines BioSpark's natural language processing system with Fifty1's AI modeling capabilities.
The initiative targets markets ranging from $1 billion to $160 billion, focusing on conditions including fatigue syndromes, cognitive decline, metabolic dysfunction, and sleep disorders. The structured database captures comprehensive therapeutic data including dosing, treatment patterns, biomarkers, and clinical responses, positioning Fifty1 Labs to accelerate therapeutic discovery through AI-guided hypothesis generation.
Fifty 1 Labs (OTC: FITY) hosted a virtual shareholder teleconference showcasing its AI-driven functional medicine strategy and leadership team. The company, operating in the $320.6 billion functional medicine market, outlined three key growth pillars: a $1 million R&D investment in AI therapies, a planned $5-10 million biotech acquisition by July 2027, and uplisting goals to OTCQB and NASDAQ.
Led by CEO Paul Arora and featuring Nobel Peace Prize recipient Dr. James Orbinski, the management team demonstrated commitment through $350,000 in personal investments and salary deferrals until reaching a $50 million valuation. The company's AI platform focuses on drug repurposing, analyzing off-patent compounds for novel therapeutic applications in wellness and functional medicine.
Fifty 1 Labs (OTC: FITY), an AI-powered health and wellness solutions company, announced a virtual shareholder teleconference scheduled for July 28, 2025, at 12:00 PM EST. The event will feature Nobel Peace Prize recipient Dr. James Orbinski and showcase the company's world-class leadership team.
The company outlined its strategic roadmap, including a $1 million R&D investment in AI therapies, plans for a $5-10 million biotech acquisition by July 2027, and intentions to uplist to OTCQB by Q1 2026. Management has demonstrated commitment by investing $350,000 personally and deferring salaries until reaching a $50 million valuation.
The leadership team includes CEO Paul Arora, Dr. James Orbinski as Senior Scientist, and other notable experts in biotech, AI, and healthcare. The company focuses on AI-driven drug repurposing in the functional medicine market, projected to grow at a 10.9% CAGR through 2030.
Fifty1 AI Labs (OTC: FITY) has announced a strategic partnership and intent to acquire BioSpark AI Technologies, marking a significant advancement in AI-driven drug repurposing. The collaboration combines BioSpark's proprietary AI and LLM platform for processing medical literature with Fifty1's predictive modeling capabilities.
The partnership aims to revolutionize drug repurposing by leveraging AI to analyze vast amounts of clinical data, focusing on performance health, chronic disease prevention, and wellness enhancement. The integration will enable automated extraction and analysis of real-world clinical data, including patient journeys and treatment outcomes, streamlining the transition from literature discoveries to clinical trials.
The acquisition will strengthen Fifty1's position in preventative healthcare through personalized, data-driven strategies and enhance their development of repurposed formulations using proprietary delivery systems.
Fifty1 AI Labs (OTC: FITY) has successfully completed the REVIVE Phase III clinical trial for Long COVID treatment, marking a significant breakthrough in AI-driven drug repurposing. The trial, conducted in collaboration with prestigious institutions including Stanford and Duke University, enrolled over 600 participants globally and represents the largest Long COVID study to date.
The company aims to achieve a $50 million valuation while targeting the $320.6 billion functional medicine market. The trial's success is powered by Fifty1's proprietary Bayesian and Predictive Platform, developed through a $1 million R&D investment. The company plans to uplist to OTCQB by Q1 2026 and eventually to NASDAQ, with upcoming product launches and a virtual shareholder teleconference scheduled for July 28, 2025.
Fifty 1 Labs (OTC: FITY) has announced an ambitious expansion plan targeting a $50 million valuation and leadership in the $320.6 billion functional medicine market. The company's management team, including a Nobel Peace Prize laureate, has demonstrated commitment through a $350,000 personal investment and salary deferrals until reaching the valuation target.
The company's Game Plan includes uplisting to OTCQB by Q1 2026 and eventually to NASDAQ, a $1,000,000 R&D investment in its AI subsidiary Fifty1 AI Labs LLC, and strategic acquisitions in the $5-10 million range. The company focuses on AI-driven drug repurposing and functional medicine, leveraging its proprietary AI platform to identify new therapeutic applications for existing drugs.
Fifty 1 Labs announces major corporate changes with Michael Lawson appointed as CEO and Chairman, while launching its new BioSentry Division. The division will focus on developing advanced biohazard sensing technology for real-time detection of biological, chemical, and environmental threats.
The company has formed a strategic partnership with UAV Corp to integrate biohazard detection with unmanned aerial vehicles. FITY shareholders will receive UMAV shares as a dividend, with details pending. The company also disclosed that its previously announced acquisition of Genetic Networks was not finalized after due diligence, and Gennaro D'Urso's employment agreement was rescinded.
Key developments include:
- BioSentry's advanced sensor technology utilizing PCR, immunoassays, and spectrometry
- Plans to pursue Department of Defense contracts
- Brandon Spikes continuing as President overseeing sports and wellness division
- Robert Clark remaining on Board of Directors
Fifty 1 Labs (OTC: FITY) and UAV Corp (OTC: UMAV) have signed a Memorandum of Understanding on April 07, 2025, forming a strategic partnership to combat biohazards through integrated technology solutions. The collaboration combines UAV Corp's aerial systems with Genetic Networks' GeneScape™ platform to develop real-time detection systems for nuclear, chemical, and biological hazards.
The two-year partnership will focus on integrating 'sniffer' technologies into UAV Corp's airships and drones, with initial testing planned at UAV Corp's Wewahitchka facility. The collaboration leverages both companies' existing Department of Defense contracts and includes developing countermeasures deployable via aerial platforms.
Key initiatives include detection systems integration, countermeasure development, distribution partnership exploration, and joint R&D combining whole-genome analysis with UAV expertise. The partnership builds on FITY's recent SpaceX Fram2 mission experiment studying yeast resistance to microgravity and cosmic radiation.
Fifty 1 Labs (FITY) announces a major space research breakthrough through its subsidiary Genetic Networks, featuring groundbreaking yeast experiments on the recent SpaceX Fram2 mission. Led by Dr. Corey Nislow, the research builds on over a decade of space-based functional genomics, from the final Space Shuttle mission to Artemis I.
The latest experiment, launched on SpaceX's Fram2 mission, involves yeast strains engineered with tardigrade-derived transgenes to study their response to microgravity and cosmic radiation. This research aims to advance applications in human radiation therapy, particularly for cancer treatments.
Dr. Nislow's work focuses on understanding life's adaptation to space conditions, with implications for pharmaceutical development and space exploration. Genetic Networks plans to expand its SpaceX collaboration with multiple missions scheduled for 2025 and beyond, strengthening Fifty 1 Labs' position in biotechnology innovation both on Earth and in space.
Fifty 1 Labs (FITY) has acquired Genetic Networks for $10 million in common shares, appointing Dr. Gennaro D'Urso as CEO and Chairman. The acquisition brings the proprietary GeneScape™ platform, which integrates genomics, AI, and machine learning to accelerate drug discovery.
The GeneScape™ technology analyzes gene-drug interactions across 6,000 genes, reducing traditional drug development timelines from 9-12 years to 2-4 years. The platform offers applications in drug repurposing, biothreat research, and food additive testing.
Genetic Networks is currently negotiating multi-million dollar contracts with the Department of Defense (DoD) for developing biothreat countermeasures. The company plans to expand operations, enhance products, and secure partnerships with pharmaceutical companies.